Objective To investigate the pathologic morphology and immunohistochemical phenotypes of sarcomatoid carcinoma(SC) of the fallopian tube.Methods One case of SC of the fallopian tube was studied under the light microscopy for morphology.Immunohistochemistry was used to detect the expression of CK,EMA,S-100,Desmin,SMA,Leu-7,CD68,actin,and Vimentin in SC tissues.Pathologic features and biological behaviors of SC were analyzed in combination with the review of literature.Results Microscopically carcinomatous and sarcomatous elements co-existed.Usually the sarcomatous element formed the bulk of the lesion.In the sarcomatous tissues,there was no distinguishable bone,cartilage,rhadomyosarcoma,etc. Immunohistochemically the strong expression of CK7,EMA and Vimentin,and the partial expression of S-100,SMA,Leu7,CD68 and actin were detected.Conclusion SC of the fallopian tube is lack of specific symptoms,and its preoperative diagnosis is difficult.B-ultrasonography,CT and MRI are helpful to the staging of SC.Final diagnosis of SC depends on pathological examination and immunohistochemistry.SC is rare,and undergoes blood metastasis in early stage.Prognosis of SC is worst.Early detection of SC is the key to improve the prognosis.

Tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 has significantly improved the survival and prognosis of patients with chronic myeloid leukemia (CML). However, long-term treatment with TKI has caused many problems like adverse drug reactions, decreasing the quality of patients' life and increasing financial burden. Therefore, whether CML patients can successfully stop taking TKI after reaching a certain therapeutic standard has become a matter of concern. At present, treatment-free remission (TFR) has already become a new target for CML therapy. Several clinical trials have confirmed the feasibility and safety of TFR in specific patient populations, and TFR is now incorporated into clinical guidelines. This paper reviews the main reasons for CML patients' pursuit of TFR and the possible mechanisms of TFR.